Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126491082 | 12649108 | 2 | F | 20160822 | 20160812 | 20160824 | EXP | US-009507513-1608USA004567 | MERCK | 30.00 | YR | M | Y | 0.00000 | 20160824 | PH | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126491082 | 12649108 | 1 | PS | REMERON | MIRTAZAPINE | 1 | Oral | 15 MG, HS | 20415 | 15 | MG | TABLET | QD | ||||||
| 126491082 | 12649108 | 2 | SS | LAMOTRIGINE. | LAMOTRIGINE | 1 | 50 MG, QD | 0 | 50 | MG | QD | ||||||||
| 126491082 | 12649108 | 3 | SS | CITALOPRAM | CITALOPRAM HYDROBROMIDE | 1 | 40 MG, QD | 0 | 40 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126491082 | 12649108 | 1 | Major depression |
| 126491082 | 12649108 | 2 | Major depression |
| 126491082 | 12649108 | 3 | Major depression |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126491082 | 12649108 | OT |
| 126491082 | 12649108 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126491082 | 12649108 | Completed suicide | |
| 126491082 | 12649108 | Drug ineffective |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |